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Abstract
Objective: PET imaging is becoming increasingly universal, and 
therefore increased liver uptake is frequently encountered. The 
purpose of this article is to describe and illustrate the various 
morphological patterns of increased metabolic activity within the 
liver with an emphasis on the diagnostic pitfalls and potential 
limitations. 
Conclusion: Knowing the pitfalls of PET imaging, correlation 
with clinical background and findings from other imaging modali-
ties are all important in the correct interpretation of increased 
hepatic activity on PET imaging. 
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Introduction
Positron emission tomography (PET) has emerged as an in-
creasingly important functional diagnostic tool in a wide spectrum 
of conditions in recent years. By far the most extensive use of 
PET/CT imaging to date has been in the diagnosis, staging and 
monitoring of malignancies. As liver is the one of the commonest 
sites of metastasis for tumours arising from the gastrointestinal 
tract, lung, breast, pancreas and melanoma etc. [1, 2] and that the 
presence of hepatic metastasis often signiﬁ cantly alters treatment 
plan, liver imaging presents a common challenge in oncological 
evaluation by PET. In the contrary, other imaging modalities such 
as ultrasound (US), dynamic CT or contrast-enhancement MRI 
remain the mainstays for diagnosis of primary liver tumours such 
as hepatocellular carcinomas (HCC). Nevertheless, occasion 
arises where whole-body PET/CT is employed as supplementary 
tool in the characterisation of known primary liver lesions or for 
various inﬂ ammatory/infective conditions. Recognizing the diffe-
rent morphological patterns of increased liver uptake is therefore 
imperative. 
PET tracers
18-ﬂ uoro-2-deoxyglucose (FDG), an analogue of glucose that 
allows evaluation of glucose metabolism, is the most commonly 
used PET tracer. FDG enters cells by glucose transporters and is in-
tracellularly phosphorylated by hexokinase into FDG-6-phosphate. 
However unlike glucose, it cannot be further metabolised and 
therefore becomes “trapped” within the cell in a manner proportional 
to the glycolytic rate. The presence of facilitated glucose transpor-
ters, especially type 1 (GLUT1) and hexokinase II, in many forms of 
solid malignancies and the consequent accelerated glycolytic rate 
is exploited in FDG-PET imaging. 
In some types of malignancy however, this alteration in tumour 
kinetics is not seen. HCCs for instance, may exhibit a higher 
glucose-6-phosphatase activity to phosphorylation kinase acti-
vity ratio, thereby resulting in a low glucose metabolism and FDG 
uptake — a fact that is well recognized for the well-differentiated 
and lower grade tumours [3]. In this regard, Carbon-11 acetate 
serves as an important complementary metabolic agent and will 
be discussed in more detail later. 
In this review article, we aimed to describe and illustrate the 
different morphological patterns of hepatic uptake that may be 
seen with these two PET tracers.
Potential diagnostic pitfalls
Before discussing the various patterns of increased hepatic 
uptake, it is useful to ﬁ rst consider the potential diagnostic pitfalls in 
PET imaging. 
Apart from the general technology-speciﬁ c pitfalls like misregis-
tration, attenuation correction and truncation artefacts etc. [4], there 
are imaging issues that speciﬁ cally relate to the liver. Normal liver, 
like the spleen, is a site of diffuse mild to moderate FDG uptake [5]. 
The usual appearance of liver parenchyma is that of a mildly 
intense, uniformly mottled appearance. This makes any increased 
uptake related to a focal lesion more difﬁ cult to be discerned from 
the background physiological activity. In an attempt to increase 
conspicuity and detection rate of liver metastasis, dual-time-point 
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FDG-PET imaging with delayed acquisition at 120mins has been 
used by some centres with success. It has been shown to be more 
sensitive in detecting liver metastases, revealing new lesions in 17% 
of patients when compared with standard imaging alone [6]. The im-
proved performance is believed to be due to altered tumour vascu-
larity and better clearance of blood-pool activity with time (Fig. 1) [7]. 
Another technique that has been proposed to improve image quality 
is the lengthening of image acquisition time (Fig. 2) [8]. 
Size is another factor that will affect the sensitivity of PET 
imaging. Studies have indicated that PET is most accurate for 
detection of hepatic metastases greater than 1 cm in diameter, 
but becomes limited when lesions are smaller than 1 cm [9, 10]. 
Age may also have a signiﬁ cant and positive impact on both 
maximum and mean standardized uptake values of the liver, as sug-
gested by Lin et al. [11]. 
Furthermore, hepatic steatosis may potentially alter hepatic 
metabolic activity on PET imaging although the difference is con-
sidered too small to be signiﬁ cant [12]. 
Morphological patterns on FDG-PET imaging
Solitary uptake
Solitary uptake in the liver is non-speciﬁ c in PET imaging  (Table 1) 
[13]. It can be due to infection (Fig. 3) or other inﬂ ammatory condi-
tions like sarcoidosis [14], histiocytosis [15] and pseudotumour [16].
 FDG is well known to accumulate in inﬂ ammatory cells such as lym-
phocytes, neutrophils and macrophages in various inﬂ ammatory or 
infectious conditions due to elevated glucose requirements [17]. 
Hence one should be aware of potential false positive results in 
such conditions. 
Primary liver tumours, either benign, malignant or metastastic 
(Fig. 4) are frequently encountered in oncological imaging. This em-
phasises the need for other imaging modalities in the evaluation of 
liver masses [18]. Benign liver tumours like haemangioma, focal 
nodular hyperplasia (FNH), and HCC have been shown to generally 
take up FDG at a similar rate as normal liver tissue [19]. Neverthe-
less, there have been case reports of increased uptake by FNH 
[20] and hepatocellular adenoma [21]. For malignant primary liver 
tumours in particular HCC, the sensitivity of FDG-PET is less than 
remarkable — a reported range of 50–65% [22, 23]. As for chol-
angiocarcinoma, the sensitivity of FDG PET is high (> 90%) for 
the intrahepatic subtype and less so for the extrahepatic subtype 
(about 60%) [24]. Uncommon liver malignancies like lymphoma, 
both primary [25] and secondary [26], and angiosarcoma [27] have 
also been reported to show increased FDG uptakes.
With regards to liver metastases, several types are known to 
have avid FDG uptake and thus FDG-PET generally has a good 
detection rate [28]. Kinkel et al. [29] found that FDG-PET is the most 
sensitive (90%) noninvasive imaging modality for the diagnosis of 
hepatic metastases from colorectal, gastric and oesophageal can-
cers. A recent meta-analysis demonstrated the sensitivities of CT, 
MR and FDG-PET for detecting hepatic metastases from colorectal 
carcinoma to be 83.6%, 88.2%, and 94.1%, respectively [30]. But 
if lesions are smaller than 1 cm in diameter, the sensitivity may be 
lower as previously explained [31, 32]. 
Ring-like uptake
Ring-like FDG uptake is also non-speciﬁ c but in the context of on-
cological imaging, it may indicate mucin-producing tumours like chol-
angiocarcinoma (Fig. 5) or metastasis from adenocarcinoma [33]. 
Mucin-producing neoplasm such as mucinous colorectal carci-
Table 1. Differential diagnosis of liver uptake lesions in FDG PET













Figure 1. 56-year-old man with carcinoma of colon and liver 
metastasis. A. Axial image of the FDG PET at 90 minutes scan has 
higher background liver activity compared with the 120 minutes 
delayed scan image B. (SUVmax 9.6, arrow; SUVmax 11.7, arrowhead)
Figure 2. 58-year-old woman with carcinoma of rectum. A. Longer 
scanning time (4 minutes per bed position) shows segment 8 HCC not 
seen on normal scanning time with mild increased metabolic activity 
(SUVmax 2.5) as compared with adjacent liver parenchyma (SUVmax 
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noma contains abundant mucin and often exhibit signiﬁ cantly lower 
peak standardized uptake values. This is believed to be secondary 
to a lower glucose metabolic rate and cellularity [34]. Presence of 
necrosis is another reason for ring-like uptake (Fig. 6). Intra-acinar 
necrosis may be seen in colorectal carcinoma [35] and can give 
rise to signiﬁ cant decrease in FDG uptake. Last but not least, 
ring-like FDG uptake within the liver is also seen in inﬂ ammatory 
conditions such as large liver abscess with liquefaction centre [13], 
or acute cholecystitis [36]. 
Multiple uptakes
In oncological imaging, multiple sites of focally increased FDG 
concentration in the background of relatively lower normal hepato-
cyte uptake are generally regarded as the hallmark of metastatic 
liver involvement from a known primary tumour (Figs. 7 and 8). 
Figure 3. 76-year-old woman presented with fever of unknown origin. 
A. Ultrasound shows a hypoechogenic lesion in the left lobe of the 
liver (arrow); B. Axial post contrast CT demonstrates a heterogeneous 
enhancing lesion (arrow); C. Patient refused biopsy and PET/CT was 
offered. Axial image of the FDG PET shows the corresponding lesion 
with increased metabolic activity SUVmax 9.3 (arrow). The patient was 
treated with antibiotics and follow-up CT showed complete resolution 
of the lesion confirming an abscess
Figure 4. 69-year-old woman with carcinoma of rectum. A. Axial 
contrast CT shows a hypoenhancing lesion in segment 2 of the 
liver (arrow) with corresponding (B) FGD PET showing a lesion 
with increased metabolic activity lesion (SUVmax 13) (arrow). 
Histopathology confirmed liver metastasis from carcinoma of rectum 
after segmentectomy
Figure 5. 67-year-old man with cholangiocarcinoma. A. Axial contrast 
CT shows a tumour in the left lobe of liver (arrow) with ductal dilation 
(arrow head); B. The left lobe lesion had a large photopenic centre 
with a rim of marked uptake (SUVmax 5.2) (arrow) on axial image 
FDG PET. Histology confirmed moderately to poorly differentiated 
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However, the differential diagnosis of liver uptake (Table 1) is still 
applicable and that correlation with clinical setting and other imag-
ing ﬁ ndings is essential for the correct diagnosis. 
Diffusely increased liver uptake (“Hepatic 
superscan”)
“Hepatic superscan” is an uncommon but interesting ﬁ nding 
in FDG-PET imaging. Analogous to the superscan seen in conven-
tional skeletal scintrigraphy, it describes the appearance of intense 
diffuse hepatic tracer uptake, often coupled with surprisingly low 
brain and cardiac FDG uptake. This appearance can be seen in 
diffuse extensive involvement by malignancy like hepatic lymphoma 
[37], HCC or metastasis [38]. Similar diffuse increase in liver FDG 
uptake from diffuse involvement by tuberculosis has been described 
as “hot liver” (Fig. 9) [39]. 
Carbon-11 acetate PET
As discussed above, the role of FDG-PET in the detection and 
diagnosis of HCC is limited. Elevated FDG uptake in malignant 
tumours largely depends on the presence of facilitated glucose 
transporters and glycolytic enzyme hexokinase II but this alteration 
in kinetic pathways does not occur in all forms of solid malignancy. 
HCC is one of such examples. As mentioned previously, many 
HCCs particularly those that are well-differentiated and lower 
grade exhibit a lower FDG avidity and may escape detection on 
FDG-PET imaging (Fig. 10). It is therefore not surprising that the 
general reported false-negative rate using FDG-PET in the imaging 
of primary HCC only approaches 50–65% [40, 41]. 
The use of Carbon-11 acetate as dual tracer is now well estab-
lished in the detection of HCC. The exact uptake mechanism of 
Carbon 11 is not known, but studies suggest that it is incorporated 
into the lipid pool in cancer tissue with low oxidative metabolism 
and high lipid synthesis [42]. An early study demonstrated that 
Figure 6. 72-year-old man with carcinoma of colon. The lesion is 
in right lobe of the liver (arrow) with increased metabolic activity 
predominantly in the periphery (SUVmax 12.8) on axial FDG PET. 
A smaller increased metabolic activity focus (arrow head) is seen in 
the lateral segment of the liver (SUVmax 5.3). Biopsy confirmed liver 
metastasis from carcinoma of colon with central necrosis
Figure 7. 79-year-old woman with carcinoma of colon. A. Axial non-
-contrast CT shows multiple hepatic hypoattenuated lesions with sized 
up to 2 cm; B. Axial FDG PET of the liver shows multiple increased 
metabolic activity with highest SUVmax 5.3 for the corresponding 
biggest lesion on CT. Features are compatible with multiple liver 
metastases. The patient succumbed one month after the PET/CT due 
to liver failure
Figure 8. 33-year-old woman with carcinoma of breast. Fused axial 
FDG PET/CT shows marked focal increased metabolic activity in the 
segment 3 (arrow) and 5 (arrow head), with SUVmax 21.0 and 15.0 
respectively. Follow-up contrast CT showed enlargement of the two 
lesions confirming the diagnosis of liver metastasis
Figure 9. 46-year-old-man with history of fever of unknown origin. 
Axial FDG PET/CT shows diffuse intense homogenous hypermetabolic 
activity in the liver (SUVmax 7.1) (arrow). Liver biopsy showed acid fast 
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Carbon-11 acetate has sensitivity for detection of HCC of 87.3% 
while that of 18F-FDG was 47.3%. When both tracers were used, 
they appeared to be complementary, giving a speciﬁ city of 100% 
[43]. As a single agent, Carbon-11 acetate appears to be more 
sensitive in detecting primary HCC that 18-F FDG (75.4% vs. 60.9%) 
although the converse is true in the case of metastatic HCC (77% 
vs. 85.7%) [44]. Carbon-11 acetate is therefore considered by many 
as complementary to 18-F FDG in HCC imaging. 
Nonetheless, it has been shown that false positive Carbon-11 
acetate uptake may occur in a variety of non-HCC hepatic le-
Figure 10. 76-year-old woman with markedly elevated alpha fetoprotein (> 60 500.0 ug/L). Dual-tracer multi-planar images from fused FDG PET/CT 
(upper row) shows negative FDG uptake in the segment V/VIII but positive 11C-acetate PET/CT (lower row) uptake (SUVmax 13.2) (arrow heads). 
Histology confirmed HCC
Figure 11. A 76-year-old man with resected segment 6 HCC. A. Follow-up dual-tracer multi-planar images from fused 11C-acetate PET/CT 
shows an increased metabolic activity area (SUVmax 8.7) at segment 3 of the liver (arrow); B. Axial post-contrast arterial phase CT shows 
a small hypervascular lesion (arrow); C. Axial post-contrast shows delayed filling of contrast on portal venous phase (arrow) consistent with 
a haemangioma. Follow-up CT at six months showed similar findings with no enlargement of the lesion
A B
sions e.g. angiomyolipoma [45] and haemangioma (Fig. 11). In 
analogy with the use of Carbon-11 acetate in the evaluation of 
 -oxidative metabolism of the myocardium [46], the large smooth 
muscular component within this unusual hepatic lesion might 
have accounted for the high uptake of Carbon-11 acetate in 
haemangioma. One study showed that Carbon-11 acetate is not 
useful in distinguishing HCC from FNH [47]. In our experience, in-
creased Carbon-11 acetate uptake due to presence of arterioportal 
shunts which are artefacts are not uncommon in cirrhotic livers and 
can be easily mistaken for HCC (Fig. 12). 
C
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Figure 12. 66-year-old man with history of HCCs and RFA treatment at segment 7 and 8. A. Dual-tracer multi-planar images from fused 11C-acetate 
PET/CT shows a small focal increased metabolic activity lesion (SUVmax 7.7) (arrow) at segment 7 of the liver, posterior to the previous RFA site; 
B. Axial post-contrast MRI image of the liver shows a wedge shape enhancing area (arrow) corresponding to the Carbon 11 acetate avid area 
(due to the present of arteroportal venous shunt). Follow-up MRI twelve months later showed no evidence of HCC
Conclusion
Abnormal liver uptake in PET imaging is a common ﬁ nding. 
Different patterns of liver uptake have been described and none of 
them are speciﬁ c to any underlying pathology. Knowing the pitfalls of 
PET imaging, correlation with clinical background and ﬁ ndings from 
other imaging modalities is the key to correctly interpreting altered 
hepatic activity. In doubtful cases, histological conﬁ rmation may 
still be required.
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